Clinical Trials Logo

Stage IB Breast Cancer AJCC v7 clinical trials

View clinical trials related to Stage IB Breast Cancer AJCC v7.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03391453 Recruiting - Clinical trials for Stage IIIC Breast Cancer AJCC v7

Proton Beam Radiation Therapy in Treating Patients With Breast Cancer After Surgery

Start date: May 10, 2016
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well proton beam radiation therapy works in treating patients with breast cancer after surgery. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors.

NCT ID: NCT02945579 Recruiting - Clinical trials for Invasive Breast Carcinoma

Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer

Start date: January 20, 2017
Phase: N/A
Study type: Interventional

This clinical trial studies eliminating surgery and how well radiation therapy after systemic therapy works in treating patients with HER2 positive or triple negative breast cancer when image-guided biopsy shows no residual cancer. Patients then receive standard breast radiotherapy.

NCT ID: NCT02912312 Recruiting - Clinical trials for Invasive Breast Carcinoma

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

Start date: February 23, 2017
Phase: Phase 2
Study type: Interventional

To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling (edema) happens, will also be studied.

NCT ID: NCT02276443 Recruiting - Clinical trials for Invasive Breast Carcinoma

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

Start date: November 9, 2015
Phase: N/A
Study type: Interventional

This clinical trial assesses whether a newly designed algorithm which looks at the genomic signature of each patient's tumor to predict their sensitivity to standard of care treatment verses being placed on a personally designed treatment trial can improve the responses in patients with newly diagnosed triple-negative breast cancer (TNBC). Testing the primary tumor biopsy for certain proteins and monitoring the lymphocyte infiltration into the tumors may help doctors determine the sub-type of TNBC, and direct treatments that may work well. It is not yet known whether assigning treatment based on the patient's tumor classification will improve how well the tumor responds.